On February 4, 2020, Kiniksa Pharmaceuticals, Ltd. and its Executive Vice President, Chief Financial Officer, Chris Heberlig, agreed that he will transition to a consulting role with the company on March 20, 2020. In connection with the transition, Kiniksa plans to enter into a consulting agreement with Mr. Heberlig, the terms of which have yet to be determined. As Kiniksa prepares for the potential commercial launch of its lead program, rilonacept (KPL-914), the company has commenced a search to appoint a new Chief Financial Officer to assist the company in its next phase of growth. On February 4, 2020, Michael Megna was appointed to the role of Chief Accounting Officer in addition to his current role as the company’s Vice President, Finance, and assumed the role of principal accounting officer from Mr. Heberlig. Upon Mr. Heberlig's transition to a consulting role, Mr. Megna will assume the role of principal financial officer from Mr. Heberlig. As the company’s Vice President, Finance (since July 2018), Mr. Megna oversees the company’s accounting and finance functions. From July 2012 until July 2018, Mr. Megna served in roles of increasing seniority at LFB USA Inc./rEVO Biologics Inc., a biopharmaceutical company, most recently as Senior Vice President, Finance & Accounting. In those roles, Mr. Megna oversaw finance, IT, human resources and project management functions.